NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
Clinical Trials
9 trialsNCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT02073123 2020-06-05
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Lumos Pharma
Phase 1/2 Completed
NCT02502708 2020-06-04
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Lumos Pharma
Phase 1 Completed
NCT01792050 2020-05-28
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Lumos Pharma
Phase 2 Completed
NCT01560923 2020-04-03
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01042535 2018-04-11
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00567931 2014-07-24
1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT01191216 2014-07-24
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed